Exhibit 10.2
AMENDMENT NO. 10
TOTRANSITIONSERVICESAGREEMENT
This Amendment No. 10 (“Amendment No. 10”) to the Agreement (as defined below) is entered into as of September 15, 2026 (the “Effective Date”) by and among BridgeBio Services Inc., a Delaware corporation (“BBIO”), TheRas, Inc., a Delaware corporation (“BBOT”), BridgeBio Pharma LLC (“BBP LLC”), and BridgeBio Oncology Therapeutics, Inc. (“PubCo”). BBIO, BBOT, BBP LLC and PubCo may be referred to herein by name or individually, as a “Party” and collectively, as the “Parties.” Capitalized terms used and not otherwise defined herein shall have the meanings given such terms in the Agreement (as defined below) to the extent defined therein.
WHEREAS,BBIOandBBOTenteredintothatcertainTransitionServices Agreement, dated April 30, 2024, as amended (the “Agreement”);
WHEREAS, the Parties now wish to further amend the Agreement to update the Service Schedule on Exhibit A thereto;
NOW, THEREFORE, in consideration of the covenants, conditions and undertakings hereinafter set forth, and for other good and valuable consideration, the receipt andsufficiency of which is hereby acknowledged, the Parties hereby agree as follows:
1.
AmendmenttoServiceSchedule.ExhibitAoftheAgreementisherebydeleted in its entirety and replaced with the following new Exhibit A attached hereto.
2.
Miscellaneous.ThisAmendmentNo. 10 together withtheAgreementconstitutestheentire agreement oftheParties withrespecttothe matters set forthinthisAmendmentNo. 10 and there are no other agreements, commitments or understandings among the Parties with respect to the matters set forth herein. All terms and conditions of the Agreement not expressly amended herein shall remain in full force and effect. The terms and conditionsof this Amendment No. 10 shall prevail over any conflicting terms and conditions in the Agreement with regard to the subject matter herein. This Amendment No. 10 shall be construed and enforced in accordance with the laws of California.
1
IN WITNESS WHEREOF, each Party hereto has executed this Amendment No. 10 as of the date first above written.
| BRIDGEBIO SERVICES INC.By: /s/ Neil KumarName: Neil KumarTitle: President & Chief Executive Officer | |
| BRIDGEBIO PHARMA LLCBy: /s/ Neil KumarName: Neil KumarTitle: President & Chief Executive Officer | |
| THERAS, INC.By: /s/ Idan ElmelechName: Idan ElmelechTitle: Chief Operating Officer | |
| BRIDGEBIO ONCOLOGY THERAPEUTICS, INC.By: /s/ Idan ElmelechName: Idan ElmelechTitle: Chief Operating Officer |
2
EXHIBIT A
SERVICE SCHEDULE
Services from July 1, 2026 through September 30, 2026
[***]
3